Dr. Pourdehnad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2252Fax+1 415-353-2765- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2012
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2005 - 2009
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2005
Certifications & Licensure
CA State Medical License 2009 - 2024
NY State Medical License 2007 - 2009
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma Start of enrollment: 2013 Dec 18
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia Start of enrollment: 2020 Aug 05
Publications & Presentations
PubMed
- 1 citationsModel based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.Fan Wu, Liangang Liu, Allison Gaudy, Xiaomin Wang, Leon Carayannopoulos, Michael Pourdehnad, Manisha Lamba> ;CPT. 2023 Oct 1
- 7 citationsPhase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, Fontanet Bijou, Thomas E Witzig, Armando Santoro, Ian W Flinn, Carola Boccomini, Vaishalee P Kenkre, Paolo Corradi...> ;Ejhaem. 2022 May 1
- 4 citationsPhase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Vincent Ribrag, Julio C Chavez, Carola Boccomini, Jason Kaplan, Jason C Chandler, Armando Santoro, Paolo Corradini, Ian W Flinn, Ranjana Advani, Philippe A Cassier, Ra...> ;Ejhaem. 2022 Feb 1
- Join now to see all
Abstracts/Posters
- A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1Michael Pourdehnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Career-Development Lunch Sessions: Industry Careers60th American Society of Hematology Annual Meeting - 12/1/2018
Press Mentions
Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016
Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient NeedsDecember 13th, 2023
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
